

Lucian Ionescu
Lucian Ionescu joined UCB in 2006, and since then, has contributed to building the immunology franchise through a track record of strategic and operational leadership roles, in Global Brand Leadership (Cimzia Pre/Launch and Commercial Implementation), Strategic Projects and Early Medicines (Bimzelx Early Development), Medical and Clinical Affairs, Global Corporate, in Europe and the United States. He built twice medical affairs organizations (Global and US), and acted as a global project leader for two launches, in rheumatology Cimzia NR axSpA and dermatology Cimzia PsO. Lucian combines passion for science with translation into patient value. He is versatile in understanding the commercial processes, marketplace dynamics, stakeholders, ecosystems, towards integration and decision-making for value creation holistically.
Lucian is a Medical Doctor (MD), and before joining UCB, has worked as a clinician in Romania, and as a scientist at University of Pennsylvania. Over his 22 yrs of professional career, he published in multiple scientific journals; he holds an MBA from Vlerick Business School, a top-100-business school, and executive degrees from Wharton, MIT, Insead and IMD (Executive Management, Artificial Intelligence and Business Strategy).
Since Sep 2019, Lucian leads the European Immunology Commercial Operations at UCB, and is responsible for evolving the business from one biologic/one therapeutic area to a portfolio of biologics across three therapeutic areas (rheumatology, dermatology, osteoporosis). Passionate about Digital Business Transformation, he and the team aspire to partner internally and externally towards contributing to digitizing and optimizing the health care system, while benefiting patients of innovative medicines across Europe during the next few years.

Evidence-based approach to medical management based on the European guidelines for HS
Latest evidence-based strategies for effective HS medical management including antibiotics and biologic therapy

Informed decisions for effective HS management
Different HS phenotypes and disease severity scores: their role in informing management decisions

The role of surgery in HS management: Optimising patient results
Surgical management of HS, through minor procedures to more complex interventions

Recognising HS symptoms: Diagnosis and what you need to know
Key criteria for diagnosing HS, common misdiagnoses and how AI can be used to assess disease severity

Taking a holistic approach: HS and its comorbidities
HS often presents with comorbidities extending beyond the skin. A holistic approach is essential for effective HS management

The invisible impact of HS: Hearing the patient experience
HS presents diverse challenges for patients, across many key aspects of life. Insights into these complex burdens provides the foundation for essential support